BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). Although randomized evidence demonstrates that imatinib (a commercially available TKI) prolongs event-free survival in patients with CML, some patients develop imatinib intolerance or resistance. In addition, imatinib is less effective in patients who have… (More)
DOI: 10.1371/currents.RRN1204

Topics

Cite this paper

@inproceedings{Terasawa2010BCRABLMT, title={BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia}, author={Teruhiko Terasawa and Issa J. Dahabreh and Thomas A. Trikalinos}, booktitle={PLoS currents}, year={2010} }